Spain (ES)

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (2021) Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, et al. Journal article Providing care for older adults in the Emergency Department: expert clinical recommendations from the European Task Force on Geriatric Emergency Medicine (2021) Lucke JA, Mooijaart SP, Heeren P, Singler K, Mcnamara R, Gilbert T, Nickel CH, et al. Journal article Cereblon enhancer methylation and IMiD resistance in multiple myeloma (2021) Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fernandez RA, et al. Journal article How Mentors Think About the Attainability of Mentoring Goals: The Impact of Mentoring Type and Mentoring Context on the Anticipated Regulatory Network and Regulatory Resources of Potential Mentors for School Mentoring Programs (2021) Mader M, Stoeger H, Veas A, Ziegler A Journal article TROPHY registry — status report (2021) Thomale UW, Auer C, Spennato P, Schaumann A, Behrens P, Gorelyshev S, Bogoslovskaia E, et al. Journal article New experimental insights into magneto-mechanical rate dependences of magnetorheological elastomers (2021) Moreno Mateos MA, Gonzalez-Rico J, Lopez-Donaire ML, Arias A, Garcia-Gonzalez D Journal article The classical two-dimensional Heisenberg model revisited: An SU(2)-symmetric tensor network study (2021) Schmoll P, Kshetrimayum A, Eisert J, Orus R, Rizzi M Journal article 2021 European myeloma network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, Van De Donk N, Terpos E, et al. Journal article, Review article Preterm birth alters the development of cortical microstructure and morphology at term-equivalent age (2021) Dimitrova R, Pietsch M, Ciarrusta J, Fitzgibbon SP, Williams LZJ, Christiaens D, Cordero-Grande L, et al. Journal article IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL (2021) Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, et al. Conference contribution